ARENA PHARMACEUTICALS INC's ticker is ARNA and the CUSIP is 040047607. A total of 2 filers reported holding ARENA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $56,001,000 | +22.2% | 602,544 | -21.7% | 0.13% | +16.4% |
| Q3 2021 | $45,834,000 | -58.1% | 769,673 | -52.0% | 0.11% | -58.3% |
| Q2 2021 | $109,449,000 | -22.1% | 1,604,833 | -20.7% | 0.26% | -26.3% |
| Q1 2021 | $140,504,000 | -1.1% | 2,024,848 | +9.5% | 0.36% | -4.5% |
| Q4 2020 | $142,052,000 | -5.7% | 1,848,914 | -8.2% | 0.38% | -22.0% |
| Q3 2020 | $150,611,000 | +65.8% | 2,013,784 | +39.5% | 0.48% | +51.3% |
| Q2 2020 | $90,842,000 | +154.3% | 1,443,094 | +69.6% | 0.32% | +101.3% |
| Q1 2020 | $35,729,000 | +694.7% | 850,710 | +1009.3% | 0.16% | +953.3% |
| Q2 2019 | $4,496,000 | -10.2% | 76,690 | -31.4% | 0.02% | -11.8% |
| Q1 2019 | $5,009,000 | +12.5% | 111,729 | -2.2% | 0.02% | +6.2% |
| Q4 2018 | $4,452,000 | -13.9% | 114,296 | +1.8% | 0.02% | +14.3% |
| Q3 2018 | $5,168,000 | -11.8% | 112,306 | -16.4% | 0.01% | -17.6% |
| Q2 2018 | $5,859,000 | +187.5% | 134,374 | +160.5% | 0.02% | +183.3% |
| Q1 2018 | $2,038,000 | – | 51,590 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 163,133 | $7,467,000 | 4.14% |
| PFM Health Sciences, LP | 2,271,536 | $103,968,000 | 3.07% |
| Partner Investment Management, L.P. | 28,877 | $1,322,000 | 2.26% |
| Atika Capital Management LLC | 181,000 | $8,284,000 | 1.74% |
| DAFNA Capital Management LLC | 93,942 | $4,300,000 | 1.62% |
| Asymmetry Capital Management, L.P. | 16,272 | $745,000 | 1.60% |
| First Light Asset Management, LLC | 190,838 | $8,735,000 | 1.32% |
| Perceptive Advisors | 953,129 | $43,624,000 | 1.18% |
| Rhenman & Partners Asset Management AB | 155,000 | $7,094,000 | 0.89% |
| Opus Point Partners Management, LLC | 9,770 | $447,000 | 0.81% |